Abstract

High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy. However, targeting MYC directly has proven difficult. We screen small molecules targeting transcriptional and epigenetic regulation, and find that THZ1 - a chemical inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC. Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but require the combined inhibition of CDK7, CDK12, and CDK13. In 11 patient derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression. Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.

Data availability

RNA sequencing data have been deposited in GEO under accession code GSE116282.

The following data sets were generated

Article and author information

Author details

  1. Mei Zeng

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  2. Nicholas P Kwiatkowski

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Nicholas P Kwiatkowski, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.
  3. Tinghu Zhang

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Tinghu Zhang, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.
  4. Behnam Nabet

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6738-4200
  5. Mousheng Xu

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  6. Yanke Liang

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  7. Chunshan Quan

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  8. Jinhua Wang

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  9. Mingfeng Hao

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  10. Sangeetha Palakurthi

    Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  11. Shan Zhou

    Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  12. Qing Zeng

    Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  13. Paul T Kirschmeier

    Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  14. Khyati Meghani

    Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  15. Alan L Leggett

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  16. Jun Qi

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  17. Geoffrey I Shapiro

    Early Drug Development Center, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  18. Joyce F Liu

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  19. Ursula A Matulonis

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  20. Charles Y Lin

    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
    For correspondence
    Charles.Y.Lin@bcm.edu
    Competing interests
    Charles Y Lin, is a consultant of Jnana Therapeutics and is a shareholder and inventor of IP licensed to Syros Pharmaceuticals.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9155-090X
  21. Panagiotis A Konstantinopoulos

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    For correspondence
    Panagiotis_Konstantinopoulos@DFCI.HARVARD.EDU
    Competing interests
    No competing interests declared.
  22. Nathanael S Gray

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    For correspondence
    nathanael_gray@dfci.harvard.edu
    Competing interests
    Nathanael S Gray, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.Is a scientific founder and equity holder of Syros Pharmaceuticals, C4 Therapeutics, Petra Pharma, Gatekeeper Pharmaceuticals, and Soltego.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5354-7403

Funding

National Cancer Institute (NIH R01 CA197336-02)

  • Nathanael S Gray

National Cancer Institute (NIH R01 CA179483-02)

  • Nathanael S Gray

U.S. Department of Defense (W81XWH-14-OCRP-OCACAOC140632 award)

  • Panagiotis A Konstantinopoulos

Cancer Prevention Research Institute of Texas (RR150093)

  • Charles Y Lin

National Cancer Institute (R01CA215452-01)

  • Charles Y Lin

American Cancer Society (Postdoctoral Fellowship PF-17-010-01-CDD)

  • Behnam Nabet

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were conducted in accordance with the animal use guidelines from the NIH and with protocols (Protocol # 11-044) approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. Full details are described in Materials and Methods - Animal Studies.

Copyright

© 2018, Zeng et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,993
    views
  • 1,091
    downloads
  • 108
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mei Zeng
  2. Nicholas P Kwiatkowski
  3. Tinghu Zhang
  4. Behnam Nabet
  5. Mousheng Xu
  6. Yanke Liang
  7. Chunshan Quan
  8. Jinhua Wang
  9. Mingfeng Hao
  10. Sangeetha Palakurthi
  11. Shan Zhou
  12. Qing Zeng
  13. Paul T Kirschmeier
  14. Khyati Meghani
  15. Alan L Leggett
  16. Jun Qi
  17. Geoffrey I Shapiro
  18. Joyce F Liu
  19. Ursula A Matulonis
  20. Charles Y Lin
  21. Panagiotis A Konstantinopoulos
  22. Nathanael S Gray
(2018)
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
eLife 7:e39030.
https://doi.org/10.7554/eLife.39030

Share this article

https://doi.org/10.7554/eLife.39030

Further reading

    1. Cancer Biology
    Bruno Bockorny, Lakshmi Muthuswamy ... Senthil K Muthuswamy
    Tools and Resources

    Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to diagnose this deadly malignancy. Analyzing circulating extracellular vesicles (cEVs) using ‘liquid biopsies’ offers an attractive approach to diagnose and monitor disease status. However, it is important to differentiate EV-associated proteins enriched in patients with pancreatic ductal adenocarcinoma (PDAC) from those with benign pancreatic diseases such as chronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN). To meet this need, we combined the novel EVtrap method for highly efficient isolation of EVs from plasma and conducted proteomics analysis of samples from 124 individuals, including patients with PDAC, benign pancreatic diseases and controls. On average, 912 EV proteins were identified per 100 µL of plasma. EVs containing high levels of PDCD6IP, SERPINA12, and RUVBL2 were associated with PDAC compared to the benign diseases in both discovery and validation cohorts. EVs with PSMB4, RUVBL2, and ANKAR were associated with metastasis, and those with CRP, RALB, and CD55 correlated with poor clinical prognosis. Finally, we validated a seven EV protein PDAC signature against a background of benign pancreatic diseases that yielded an 89% prediction accuracy for the diagnosis of PDAC. To our knowledge, our study represents the largest proteomics profiling of circulating EVs ever conducted in pancreatic cancer and provides a valuable open-source atlas to the scientific community with a comprehensive catalogue of novel cEVs that may assist in the development of biomarkers and improve the outcomes of patients with PDAC.

    1. Cancer Biology
    2. Evolutionary Biology
    Lingjie Zhang, Tong Deng ... Chung-I Wu
    Research Article

    Tumorigenesis, like most complex genetic traits, is driven by the joint actions of many mutations. At the nucleotide level, such mutations are cancer-driving nucleotides (CDNs). The full sets of CDNs are necessary, and perhaps even sufficient, for the understanding and treatment of each cancer patient. Currently, only a small fraction of CDNs is known as most mutations accrued in tumors are not drivers. We now develop the theory of CDNs on the basis that cancer evolution is massively repeated in millions of individuals. Hence, any advantageous mutation should recur frequently and, conversely, any mutation that does not is either a passenger or deleterious mutation. In the TCGA cancer database (sample size n=300–1000), point mutations may recur in i out of n patients. This study explores a wide range of mutation characteristics to determine the limit of recurrences (i*) driven solely by neutral evolution. Since no neutral mutation can reach i*=3, all mutations recurring at i≥3 are CDNs. The theory shows the feasibility of identifying almost all CDNs if n increases to 100,000 for each cancer type. At present, only <10% of CDNs have been identified. When the full sets of CDNs are identified, the evolutionary mechanism of tumorigenesis in each case can be known and, importantly, gene targeted therapy will be far more effective in treatment and robust against drug resistance.